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The off-label use of drugs is common, particularly in 
paediatrics, where many drugs have yet to undergo the 
rigorous scrutiny demanded by authorities such as the 
Medicines Control Council (MCC) and the US Food and 
Drug Administration (FDA) before registration.1,2 Yet some 
drugs (e.g. paracetamol, salbutamol) are so commonplace in 
paediatric practice that it may come as a surprise that their 
use is indeed off-label in many circumstances. Problems may 
arise when an important drug in everyday (off-label) use is 
unexpectedly in short supply. An example is dinoprostone, 
marketed in South Africa as Prostin E2 by Pfizer South Africa 
(but curiously not listed on their website). Its registered 
use in South Africa is for induction of labour (as an oral 0.5 
mg tablet), yet it is commonly used in South Africa for the 
emergency maintenance of ductal patency in newborn babies. 
Dinoprostone
Dinoprostone is a naturally occurring prostaglandin E2 that 
binds and activates the PGE2 receptor. It is often used as an 
emergency treatment to maintain the patency of the ductus 
arteriosus (PDA) in neonates with duct-dependent lesions 
such as certain forms of cyanotic congenital heart disease (e.g. 
pulmonary atresia or transposition of the great arteries) and 
interruption or coarctation of the aorta. The birth incidence 
of these rapidly life-threatening lesions is 1.0 - 1.8/1 000 3 and 
administration of dinoprostone is life-saving, ‘buying time’ 
for the baby to be transferred to a referral centre for definitive 
establishment of pulmonary or aortic blood flow by systemic-
to-pulmonary shunt or arch repair, respectively. Without 
maintenance of ductal patency, duct-dependent babies rapidly 
become critically ill and die. 
Dinoprostone is also used for the longer-term maintenance 
of ductal patency in low-birth-weight infants with duct-
dependent pulmonary circulations but branch pulmonary 
arteries that are too small for immediate surgical placement of 
a systemic-to-pulmonary artery shunt.4 
For these applications, dinoprostone is usually administered 
as an oral medication. The 0.5 mg tablet is crushed and mixed 
with water and 0.125 mg aliquots (¼ tablet) are given to the 
infant by nasogastric tube every 30 - 60 minutes.4 The side-
effects are minimal, but include a small increase in body 
temperature (generally to less than 37.5°C) and loose stools. 
This simple method of administration is easily achievable 
by peripheral hospitals and delivery units, enabling rapid 
establishment of stable ductal patency before transfer to a 
tertiary referral centre. 
An alternative, intravenous PGE1 (alprostadil, Prostin 
VR), requires the placement of secure intravenous access 
for continuous infusion of alprostadil and close monitoring 
of respiratory effort. Intravenous PGE1 frequently causes 
apnoea requiring intubation and ventilation for safe transfer. 
Peripheral hospitals and delivery units are often not capable of 
such interventions and do not stock intravenous PGE1. There 
are no alternatives to maintain ductal patency.
The whistle-blower case
In January 2009 we received a call from a paediatrician at 
a regional hospital. A small infant with pulmonary atresia, 
dependent on a PDA for flow to his pulmonary arteries, 
required time to grow to sufficient size to enable the placement 
of a modified Blalock-Taussig shunt. After assessment at Red 
Cross War Memorial Children’s Hospital he had been returned 
to the regional hospital for growth,  receiving a quarter 
Prostin E2 tablet half-hourly for maintenance of his PDA. The 
hospital was about to run out of Prostin E2 and was unable 
to replenish the supply from local clinics or hospitals, since 
these had all also run out. No stocks were available from local 
suppliers. The baby was transferred back to Red Cross Hospital 
on intravenous alprostadil, and required early placement of 
a systemic-to-pulmonary artery shunt. The procedure was 
complicated by early shunt stenosis and re-operation was 
required for shunt revision, which could have been avoided 
had he been allowed to grow until the vessels were larger, 
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Where had all the Prostin gone? 
Unbeknown to South African paediatric cardiologists and 
most pharmacists nationally, stocks of Prostin E2 had become 
critically depleted. Pfizer is said to have redesigned the 
packaging of Prostin E2, and stocks became depleted while 
awaiting re-registration with the Medicines Control Council. 
Why did Pfizer fail to inform paediatric cardiologists 
and pharmacists of an imminent and foreseeable shortage? 
Apparently Pfizer representatives had informed obstetric/
gynaecological practitioners, but according to their 
spokesperson they were ‘not allowed’ to discuss an off-label 
drug with paediatric cardiologists, despite the fact that Prostin 
E2 is the only oral dinoprostone available in South Africa and 
has been in use as outlined for many years. A rapid survey of 
all paediatric cardiac referral centres in South Africa revealed 
that this was a national problem in both the public and private 
health sectors. At the same time, Pfizer could not tell us with 
certainty when supplies would be resumed.
To their credit, when the potential impending crisis in 
congenital cardiac care was brought to Pfizer’s attention in 
mid-January 2009, they expedited the delivery of fresh stocks 
to suppliers, and by Monday 26 January the supply of Prostin 
E2 had resumed nationwide. Pfizer assured us that there was 
sufficient stock ‘for two years’ and that future supplies would 
be ‘uninterrupted’, but unfortunately were not prepared to give 
these assurances in writing. 
So ended a brief yet worrying period during which we could 
not ensure the safe transfer of neonates with duct-dependent 
congenital cardiac lesions and were having to start making 
difficult management decisions with regard to timing of 
their cardiac surgery. Nevertheless, it remains of concern that 
the supply of essential and life-saving drugs can be prone 
to sudden, unexpected interruptions; and perhaps more so 
that producers consider themselves legally constrained from 
disclosing imminent foreseeable drug supply interruptions if 
such drugs are used off-label. The reluctance of pharmaceutical 
companies to discuss issues pertinent to the use of off-label 
drugs – even urgent issues such as notification of interruption 
of supply – is grounds for much concern. It surprises us 
that medical practitioners working for this company are 
not prepared to inform colleagues – even ‘off the record’ – 
considering that Prostin is listed for paediatric use in the latest 
version of the essential drugs list for South Africa.5 
The FDA becomes permissive
In the USA, the FDA’s prohibition on pharmaceutical 
companies to inform medical practitioners of important 
changes in indications for off-label drugs has been judged in 
the US District Court of Columbia as unconstitutional, and the 
FDA’s restrictive stance vigorously criticised. The judgment 
included the statement: ‘In sum, the court finds that the 
restrictions in the Guidance Documents [of the FDA] are more 
extensive than necessary to serve the asserted government 
interest and that they unduly burden important speech.’6   In 
essence, the district court therefore had found that the FDA 
had violated the First Amendment of the US Constitution.  On 
appeal, the US Court of Appeals for the District of Columbia 
dismissed the finding of the district court  pertaining to the 
unconstitutionality of the FDA’s prohibitions on procedural 
grounds, since it ‘was not ripe for decision’, but noted that it 
‘certainly did not criticize the reasoning or conclusions of the 
district court’.7
Thereafter, the FDA reconsidered its role in the regulation 
of off-label drug use, suggesting ‘a more permissive attitude 
toward the promotion of off-label uses of drugs’.8 In its 
recently published ‘Guidance for Industry’ document9 the FDA 
recognises ‘that the public health can be served when health 
care professionals receive truthful and non-misleading scientific 
and medical information on unapproved uses of approved or 
cleared medical products’. 
Conclusion
While US law is not necessarily applicable in South Africa, 
surely common sense demands that in the interests of public 
health, information of a life-threatening shortage of any drug, 
Pfizer responds 
Pfizer South Africa welcome this article, which seeks 
to inform and protect the interests of both patients and 
physicians, and thank SAMJ for the opportunity to clarify 
some of the points made for the benefit of readers.
Product shortages do occur from time to time for a variety 
of reasons. In the case of Prostin E2 we found ourselves in 
an unfortunate situation whereby our third party supplier 
ran out of stock. This was totally unexpected and, because 
they are a third party supplier, resulted in our having to 
follow a number of different logistical as well as regulatory 
processes. 
Keeping patients and physicians informed and 
protecting their interests is of paramount importance to 
Pfizer South Africa, and we greatly appreciate feedback. 
We will incorporate De Decker et al.’s suggestions in our 
communications to ensure that all relevant health care 
professionals are promptly informed of such issues within 
the confines of the industry regulations, and assure readers 
of our commitment to providing uninterrupted access to 
our medicines for patients and physicians. 
Brian Daniel
CEO and Country Manager
Pfizer South Africa
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even in off-label use, should be disseminated as widely as 
possible to relevant health professionals. This would allow 
clinicians and pharmacists to implement contingency plans 
and/or changes in management strategies in order to minimise 
potential loss of life or increased morbidity resulting from the 
shortage of the drug. 
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